Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 29Pancreatic Neoplasms 25Colonic Neoplasms 25Neoplasm Metastasis 19Stomach Neoplasms 17Neoplasms 17Esophageal Neoplasms 17Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Breast Neoplasms 10Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 6Cholangiocarcinoma 6Carcinoma, Squamous Cell 6Gallbladder Neoplasms 5Carcinoma, Hepatocellular 5Bile Duct Neoplasms 5Liver Neoplasms 4Anus Neoplasms 4Lung Neoplasms 3Triple Negative Breast Neoplasms 2Somatostatinoma 2Sarcoma 2Peritoneal Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Everolimus 2romidepsin 1pentetreotide 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Doxorubicin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrinoma × Fluorouracil × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡